Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$17,500.00

Relationships between plasma biomarkers, neuroimaging biomarkers and cognitive impairment in cerebral amyloid angiopathy

FY 2021-22

Summary
Alzheimers Disease (AD) is the most common cause of dementia ; a devastating condition that impairs memory and leads to immeasurable stress to families. Dementia currently costs our system $10.3 billion/year, and the number of Canadians living with dementia will double in the next decade. In AD, toxic proteins (amyloid beta and tau) accumulate and cause brain degeneration. In some, amyloid can accumulate in and cause damage to small blood vessels in a process called Cerebral Amyloid Angiopathy (CAA). CAA can cause bleeds in the brain that lead to cognitive impairment, disability, and death. Diagnosing and detecting CAA early is challenging. New technologies now allow us to measure the levels of amyloid beta and tau in the blood and could lead to the early detection of CAA. However, no studies have examined the blood levels of amyloid beta or tau in patients with CAA.The objective of our study is to test for and compare the blood levels of amyloid beta and tau between the following groups: (i) those with CAA (ii) those with AD but no CAA and (iii) healthy adults. We will examine whether differences exist in the levels of amyloid and tau between these groups. Our second objective is to see whether the blood levels of amyloid and tau may also be associated with the degree of (i) memory impairment and (ii) damage to the brains structure seen on Magnetic Resonance Imaging (MRI). If our study identifies a unique blood profile of amyloid and/or tau in those with CAA, it could potentially justify the use of these blood tests in future. This project may provide new insights into underlying disease mechanisms in CAA, lead to improved assessment and care, and potentially give rise to clinical tools to better evaluate patients with cognitive impairment.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
466538
Name
Muir Ryan T
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Relationships between plasma biomarkers, neuroimaging biomarkers and cognitive impairment in cerebral amyloid angiopathy
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Amyloid Beta; Biomarkers; Cerebral Amyloid Angiopathy; Cognitive Impairment; Dementia; Magnetic Resonance Imaging; Neurofilament Light Chain; Small Vessel Disease
Abstract
Alzheimers Disease (AD) is the most common cause of dementia ; a devastating condition that impairs memory and leads to immeasurable stress to families. Dementia currently costs our system $10.3 billion/year, and the number of Canadians living with dementia will double in the next decade. In AD, toxic proteins (amyloid beta and tau) accumulate and cause brain degeneration. In some, amyloid can accumulate in and cause damage to small blood vessels in a process called Cerebral Amyloid Angiopathy (CAA). CAA can cause bleeds in the brain that lead to cognitive impairment, disability, and death. Diagnosing and detecting CAA early is challenging. New technologies now allow us to measure the levels of amyloid beta and tau in the blood and could lead to the early detection of CAA. However, no studies have examined the blood levels of amyloid beta or tau in patients with CAA.The objective of our study is to test for and compare the blood levels of amyloid beta and tau between the following groups: (i) those with CAA (ii) those with AD but no CAA and (iii) healthy adults. We will examine whether differences exist in the levels of amyloid and tau between these groups. Our second objective is to see whether the blood levels of amyloid and tau may also be associated with the degree of (i) memory impairment and (ii) damage to the brains structure seen on Magnetic Resonance Imaging (MRI). If our study identifies a unique blood profile of amyloid and/or tau in those with CAA, it could potentially justify the use of these blood tests in future. This project may provide new insights into underlying disease mechanisms in CAA, lead to improved assessment and care, and potentially give rise to clinical tools to better evaluate patients with cognitive impairment.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Muir, Ryan T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~